Bacterial Vaginosis Market Size Set for Strong CAGR-Driven Growth Through 2034

The Bacterial Vaginosis market size is anticipated to grow with a significant CAGR during the study period (2020-2034). DelveInsight’s comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Bacterial Vaginosis landscape.

Another approved treatment is VIVAGEL BV, a mucoadhesive gel that received approval in Europe in 2019. It is the first non-antibiotic option for preventing recurrent bacterial vaginosis. Additionally, the product has been granted both QIDP and Fast Track designations for its indications across various markets.

The analysis indicates that bacterial vaginosis is the most common vaginal infection among women of reproductive age, impacting approximately 5–70% of women. In the United States, its prevalence is estimated to be around 30%. The condition affects women between the ages of 14 and 49, with notable variations across ethnic groups and a higher occurrence among non-white populations. Additionally, bacterial vaginosis is present even in women with no history of vaginal, oral, or anal sexual activity, affecting nearly 18.8% of this group.

DelveInsight’s report, “Bacterial Vaginosis Market Insights, Epidemiology, and Market Forecast-2034” provides a comprehensive analysis of the Bacterial Vaginosis landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines Bacterial Vaginosis market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To Know in detail about the Bacterial Vaginosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Bacterial Vaginosis Market Forecast

Some of the key facts of the Bacterial Vaginosis Market Report:

• Daré announced that the US FDA has approved XACIATO (clindamycin phosphate) vaginal gel, 2% (previously known as DARE-BV1) for treating bacterial vaginosis in females aged 12 years and older. In March 2022, Organon and Daré Bioscience, Inc. also entered into an agreement under which Organon obtained global licensing rights to XACIATO.
• Key Bacterial Vaginosis Companies: Organon/Daré Bioscience, Lupin, Osel, and others
• Key Bacterial Vaginosis Therapies: XACIATO, SOLOSEC, LACTIN-V, and others
• The Bacterial Vaginosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Bacterial Vaginosis pipeline products will significantly revolutionize the Bacterial Vaginosis market dynamics.

Bacterial Vaginosis Overview

Bacterial Vaginosis is a common vaginal infection caused by an imbalance in the natural bacteria found in the vagina. Normally, "good" bacteria like Lactobacillus dominate, but in BV, there is an overgrowth of "bad" bacteria. Symptoms may include abnormal vaginal discharge, a fishy odor, itching, or burning. While BV is not a sexually transmitted infection, it can be influenced by sexual activity, douching, or an imbalance in the vaginal environment. Treatment typically involves antibiotics to restore bacterial balance.

Get a Free sample for the Bacterial Vaginosis Market Forecast, Size & Share Analysis Report: Bacterial Vaginosis Market

 

Key Trends in Bacterial Vaginosis Therapeutics Market:

• Shift toward microbiome-based and recurrence-focused therapies: Treatment strategies are evolving beyond antibiotics to include probiotics, microbiome restoration, and biofilm-disrupting therapies aimed at reducing high recurrence rates.
• Increasing adoption of combination and multi-mechanism treatments: Combination regimens (antibiotic + adjunct therapies) are gaining traction to improve efficacy and prevent relapse, addressing limitations of monotherapy.\
• Advancements in drug delivery systems: Innovations such as sustained-release formulations, topical gels, and vaginal delivery systems are improving patient compliance and therapeutic outcomes.
• Rising focus on early diagnosis and point-of-care testing: Improved diagnostic tools and increased awareness are driving earlier detection, leading to higher treatment uptake and market expansion.
• Growing demand for OTC and accessible treatment options: Expansion of over-the-counter products and e-commerce channels is making BV treatments more accessible, supporting market growth globally

Bacterial Vaginosis Epidemiology

The Bacterial Vaginosis epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Bacterial Vaginosis Epidemiology Segmentation:

The Bacterial Vaginosis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Bacterial Vaginosis
• Prevalent Cases of Bacterial Vaginosis by severity
• Gender-specific Prevalence of Bacterial Vaginosis
• Diagnosed Cases of Episodic and Chronic Bacterial Vaginosis

Download the report to understand which factors are driving Bacterial Vaginosis epidemiology trends @ Bacterial Vaginosis Epidemiology Forecast

Recent Development In The Bacterial Vaginosis Treatment Landscape:

• In August 2025, Evofem Biosciences, Inc. (OTCID: EVFM) announced that a recently granted U.S. patent for SOLOSEC® (secnidazole) 2 g oral granules, along with one of its approved indications, has been included in the U.S. Food and Drug Administration’s (FDA) publication Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book).

Bacterial Vaginosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Bacterial Vaginosis market or expected to get launched during the study period. The analysis covers Bacterial Vaginosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Bacterial Vaginosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies..

Bacterial Vaginosis Therapies and Key Companies

• XACIATO: Organon/Daré Bioscience
• SOLOSEC: Lupin
• LACTIN-V: Osel

Discover more about therapies set to grab major Bacterial Vaginosis market share @ Bacterial Vaginosis Treatment Landscape

Bacterial Vaginosis Market Drivers

• High Disease Prevalence: Bacterial vaginosis is one of the most common vaginal infections among women of reproductive age, driving strong demand for treatment options.
  Increasing Awareness and Screening: Growing focus on women’s health and sexual health awareness is improving diagnosis and treatment rates.
• Association with Other Health Risks: Links to sexually transmitted infections (STIs), pregnancy complications, and infertility are boosting the need for effective management.
• Advancements in Therapeutics: Development of novel antibiotics, probiotics, and microbiome-based therapies is expanding treatment options.
• Rising R&D and Product Development: Increased investments by pharmaceutical companies are accelerating pipeline growth and innovation.

Bacterial Vaginosis Market Barriers

• High Recurrence Rates: Frequent relapse after treatment remains a major challenge, limiting long-term effectiveness of current therapies.
• Limited Treatment Differentiation: Existing therapies, mainly antibiotics, offer similar mechanisms and outcomes, restricting innovation impact.
• Antibiotic Resistance Concerns: Overuse of antibiotics may reduce efficacy and hinder treatment success over time.
• Underdiagnosis and Social Stigma: Lack of awareness and reluctance to seek medical care can limit diagnosis and treatment uptake.
• Access and Affordability Issues: Limited healthcare access in developing regions may restrict market growth.

Scope of the Bacterial Vaginosis Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Bacterial Vaginosis Companies: Organon/Daré Bioscience, Lupin, Osel, and others
• Key Bacterial Vaginosis Therapies: XACIATO, SOLOSEC, LACTIN-V, and others
• Bacterial Vaginosis Therapeutic Assessment: Bacterial Vaginosis current marketed and Bacterial Vaginosis emerging therapies
• Bacterial Vaginosis Market Dynamics: Bacterial Vaginosis market drivers and Bacterial Vaginosis market barriers 
• Bacterial Vaginosis Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Bacterial Vaginosis Unmet Needs, KOL’s views, Analyst’s views, Bacterial Vaginosis Market Access and Reimbursement 

To know more about Bacterial Vaginosis companies working in the treatment market, visit @ Bacterial Vaginosis Clinical Trials and Therapeutic Assessment

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.